

1 **Appendix - Unadjusted and adjusted estimates of attrition (death and loss to follow-up) at one-year**
 2 **and ever after ART initiation among 12,219 patients who initiated antiretroviral therapy between**
 3 **January 2008 and December 2013 at the Themba Lethu Clinic in Johannesburg, South Africa**

| Characteristic | One-year after ART initiation | | Ever after ART initiation | |
|--|-------------------------------|-------------------------|---------------------------|-------------------------|
| | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
| Citizenship status | | | | |
| Confirmed South African citizen | Reference | Reference | Reference | Reference |
| Unconfirmed South African citizen | 3.15 (2.90, 3.41) | 2.72 (2.51, 2.95) | 2.99 (2.80, 3.19) | 2.70 (2.52, 2.88) |
| Foreign national | 1.02 (0.89, 1.17) | 1.09 (0.95, 1.25) | 0.95 (0.85, 1.05) | 0.97 (0.87, 1.08) |
| Year of ART initiation | | | | |
| 2008-09 | Reference | -- | Reference | Reference |
| 2010-11 | 0.93 (0.86, 1.02) | -- | 0.91 (0.85, 0.97) | 1.11 (1.01, 1.21) |
| 2012-13 | 0.94 (0.86, 1.04) | -- | 0.84 (0.77, 0.91) | 1.17 (1.06, 1.30) |
| Sex | | | | |
| Male | 1.51 (1.40, 1.63) | 1.44 (1.32, 1.57) | 1.48 (1.40, 1.57) | 1.47 (1.37, 1.57) |
| Female | Reference | Reference | Reference | Reference |
| Age at ART initiation | | | | |
| <30 | 1.07 (0.95, 1.20) | 0.93 (0.83, 1.05) | 1.27 (1.16, 1.39) | 1.15 (1.05, 1.26) |
| 30-34.9 | 0.94 (0.84, 1.05) | 0.81 (0.72, 0.91) | 1.10 (1.01, 1.21) | 1.00 (0.92, 1.10) |
| 35-39.9 | 0.98 (0.87, 1.09) | 0.88 (0.78, 0.98) | 0.98 (0.90, 1.08) | 0.91 (0.83, 0.99) |
| 40-44.9 | 0.95 (0.84, 1.07) | 0.91 (0.80, 1.03) | 0.95 (0.86, 1.05) | 0.93 (0.84, 1.03) |
| ≥45 | Reference | Reference | Reference | Reference |
| Employment status | | | | |
| Employed | Reference | Reference | Reference | Reference |
| Unemployed | 1.59 (1.47, 1.71) | 1.36 (1.26, 1.47) | 1.55 (1.46, 1.64) | 1.39 (1.30, 1.47) |
| Baseline CD4 count (cells/mm³) | | | | |
| <50 | 2.89 (2.55, 3.28) | 1.85 (1.61, 2.11) | 2.22 (2.03, 2.44) | 1.59 (1.44, 1.75) |
| 50-99 | 1.93 (1.68, 2.22) | 1.39 (1.20, 1.60) | 1.62 (1.46, 1.79) | 1.27 (1.14, 1.42) |
| 100-199 | 1.37 (1.20, 1.56) | 1.18 (1.03, 1.35) | 1.35 (1.23, 1.49) | 1.23 (1.11, 1.35) |
| ≥200 | Reference | Reference | Reference | Reference |
| BMI at ART initiation (kg/m²) | | | | |
| <18.5 | 1.82 (1.64, 2.00) | 1.31 (1.17, 1.45) | 1.64 (1.52, 1.78) | 1.27 (1.16, 1.38) |
| 18.5-24.9 | Reference | Reference | Reference | Reference |
| 25-29.9 | 0.59 (0.51, 0.68) | 0.79 (0.69, 0.92) | 0.65 (0.59, 0.73) | 0.85 (0.76, 0.95) |
| ≥30 | 0.49 (0.40, 0.60) | 0.75 (0.60, 0.92) | 0.56 (0.49, 0.65) | 0.81 (0.69, 0.94) |
| WHO Stage | | | | |
| I/II | Reference | Reference | Reference | Reference |
| III/IV | 1.97 (1.82, 2.12) | 1.24 (1.13, 1.35) | 1.67 (1.58, 1.78) | 1.18 (1.10, 1.27) |
| Anemia at ART initiation | | | | |
| No Anemia | Reference | Reference | Reference | Reference |
| Mild Anemia | 1.40 (1.23, 1.60) | 1.13 (0.98, 1.29) | 1.22 (1.11, 1.33) | 1.04 (0.94, 1.14) |
| Moderate Anemia | 2.04 (1.82, 2.28) | 1.53 (1.36, 1.74) | 1.56 (1.43, 1.69) | 1.27 (1.16, 1.39) |
| Severe Anemia | 3.77 (3.28, 4.32) | 2.36 (2.02, 2.75) | 2.47 (2.22, 2.75) | 1.74 (1.55, 1.96) |
| Co-infected with tuberculosis at ART initiation | | | | |
| No | Reference | Reference | Reference | Reference |
| Yes | 1.54 (1.39, 1.70) | 0.90 (0.80, 1.00) | 1.52 (1.40, 1.65) | 0.99 (0.90, 1.08) |
| First ART regimen^λ | | | | |

| | Reference | Reference | Reference | Reference |
|-------------|-------------------|-------------------|-------------------|-------------------|
| TDF-3TC-EFV | | | | |
| d4T-3TC-EFV | 1.15 (1.06, 1.24) | 0.90 (0.83, 0.98) | 1.20 (1.12, 1.28) | 1.06 (0.98, 1.16) |
| AZT-3TC-EFV | 1.31 (1.05, 1.65) | 1.19 (0.94, 1.50) | 1.22 (1.01, 1.48) | 1.15 (0.95, 1.41) |
| Other | 0.80 (0.70, 0.92) | 0.91 (0.79, 1.04) | 0.94 (0.85, 1.05) | 1.02 (0.91, 1.14) |

4 ^λTDF=Tenofovir; 3TC=lamivudine; EFV=efavirenz; d4T=stavudine; AZT=zidovudine; Other regimens are: TDF-3TC-NVP
5 (nevirapine), AZT-3TC-NVP, TDF-EMT (emtricitabine)-EFV, TDF-EMT-NVP, and d4T-3TC-NVP